| Pharmacogenetic profiling in the treatment of heart disease. | |
| | |
MedLine Citation:
|
PMID: 19931195 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Pharmacogenetics is the study of gene-drug interactions. In the post-Human Genome era, and with the realization that personal genotypes differ by millions of bases (gene polymorphisms), the application of genetics to explain interindividual differences in clinical drug response seems to offer great promise. Here, recent basic and translational developments in pharmacogenetic profiling of beta-blocker response in heart failure are reviewed in the context of the possible consequences of such advances on drug development and clinical therapeutics. |
| | |
Authors:
|
Gerald W Dorn |
Related Documents
:
|
2831355 - Pharmacogenetics of psychoactive drugs. 11256585 - Current pharmacogenomic approaches to clinical drug development. 22110915 - Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients? 19514905 - Hla-b*5701 screening prior to abacavir prescription: clinical and laboratory aspects. 18770085 - The impact of opiate agonist maintenance therapy on drug use within social networks of ... 2268415 - Traces of brain microtubule-associated proteins affect dynamic properties of microtubules. |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Review Date: 2009-08-12 |
Journal Detail:
|
Title: Translational research : the journal of laboratory and clinical medicine Volume: 154 ISSN: 1878-1810 ISO Abbreviation: Transl Res Publication Date: 2009 Dec |
Date Detail:
|
Created Date: 2009-11-25 Completed Date: 2009-12-15 Revised Date: 2011-03-03 |
Medline Journal Info:
|
Nlm Unique ID: 101280339 Medline TA: Transl Res Country: United States |
Other Details:
|
Languages: eng Pagination: 295-302 Citation Subset: AIM; IM |
Affiliation:
|
Center for Pharmacogenomics, Department of Medicine, Washington University School of Medicine, St Louis, Mo., USA. gdorn@dom.wustl.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenergic beta-Antagonists
/
therapeutic use Animals Cytochrome P-450 CYP2D6 / genetics Gene Expression Profiling* Heart Diseases / drug therapy, genetics, therapy* Humans Mice Mice, Transgenic Pharmacogenetics* Polymorphism, Genetic |
| Grant Support | |
ID/Acronym/Agency:
|
P50 HL077101/HL/NHLBI NIH HHS; R01 HL087871/HL/NHLBI NIH HHS; R01 HL087871-04/HL/NHLBI NIH HHS; RC2 HL102222-01/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; EC 1.14.14.1/Cytochrome P-450 CYP2D6 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: "Personalizing" academic medicine: opportunities and challenges in implementing genomic profiling.
Next Document: Personalized medicine: individualized care of cancer patients.